Biotechnology
Zylox-Tonbridge Announces Financial Results for 2022: Revenue Increases by 87.8% YOY to RMB 334 million and Gross Profit Reaches RMB 253 million
HANGZHOU, China, March 30, 2023 /PRNewswire/ -- On March 29, 2023, Zylox-Tonbridge Medical Technology Co., Ltd. (2190. HK, hereinafter referred to as the "Company") released its annual financial results for 2022. During the reporting period, the Company's operating revenue increased by 87.8% YOY ...
ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China
SHENZHEN, China, March 29, 2023 /PRNewswire/ -- ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical Products Administration ("NMPA") for Phase I clinical trial inChina on March 29, 2023. Previously, MVR-C5252 also obt...
bitBiome and Kaken Pharmaceuticals sign joint research agreement on the discovery of drugs for infectious diseases
-The joint research will use bitBiome's drug discovery platform technology to search for drug candidate substances- TOKYO, March 29, 2023 /PRNewswire/ -- bitBiome, Inc. (Head office: Shinjuku-ku,Tokyo; President: Yuji Suzuki; hereafter 'bitBiome') and Kaken Pharmaceuticals (Head office: Bunkyo-k...
Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China
SUZHOU, China, March 28, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 740 subjects recently for...
Tigermed Reports Full Year 2022 Results
HANGZHOU, China, March 28, 2023 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its an...
OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab
SHENZHEN, China, March 28, 2023 /PRNewswire/ -- OncoVent Co., Ltd. ("OncoVent"), a majority-controlled subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company"), yesterday entered into a license agreement with Orient EuroPharma Co., Ltd. ("OEP"). According to the terms of th...
Acepodia to Present Preclinical Data of Gamma Delta T cell Therapy Candidate, ACE2016, an off-the-shelf EGFR-targeting γδ2 T cell therapy against EGFR-expressing solid tumors
ALAMEDA, Calif. and TAIPEI, March 27, 2023 /PRNewswire/ -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique antibody-cell conjugation (ACC) technology to address gaps in cancer care, today announced the upcoming poster presentation of new ...
BJ Bioscience Announces Clinical Collaboration with MSD to Evaluate BJ-001 in Combination with KEYTRUDA® (pembrolizumab)
SHANGHAI, March 27, 2023 /PRNewswire/ -- BJ Bioscience, Inc. BJ Bioscience, a biotech company focusing on discovery and development of novel biologics for cancer immunotherapy, today announced that it entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc.,Rah...
BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies
Exclusive Research and Option Agreement With Global Biopharmaceutical Company to Leverage BIORCHESTRA Targeting Technology Platform -BDDS™ - to Develop Nucleic Acid Therapies for Treatment of Neurological Disorders in Multiple Targets CAMBRIDGE, Mass. and DAEJEON, South Korea, March 27, 2023 /PR...
ProfoundBio Highlights Broad Antitumor Activity in Preclinical Models and Trial-in-Progress for PRO1184 at AACR 2023 Annual Meeting
WOODINVILLE, Wash. and SUZHOU, China, March 24, 2023 /PRNewswire/ -- ProfoundBio, a clinical stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential, will present two posters from its lead program, PRO1184, a folate receptor alpha (FRα)-...
AnPac Bio-Medical Science Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting the Equity Rule on or before July 12, 2023
NEW YORK, March 23, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States andChina focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platf...
Ascentage Pharma Announces 2022 Annual Results Including Strong Sales of Olverembatinib and Steady Progress in Transition Towards Biopharma
SUZHOU, China and ROCKVILLE, Md., March 22, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2022. During...
CARsgen Announced 2022 Annual Results and Business Updates
SHANGHAI, March 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2022 Annual Results. Business Highlights * Zevor-cel (CT053)...
Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023
NEWARK, Del., March 22, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology company, today announced the upcoming presentations of non-clinical data from its oncology pipeline, including BSI-507: anti-PD1ⅹanti-PVRIG bispecific antibody and BSI-508: anti-PD1ⅹanti-CD47 bis...
Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer
BEIJING, SHANGHAI and BOSTON, March 22, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has entered into a clinical collaboration with Merck & Co., Inc.,Rahway, NJ, USA to evaluate the combination of Jacobio's CD73 monoclonal antibody JAB-BX102 in combination with Merck & Co., Inc., Ra...
280Bio Provides Update on the KRAS Inhibitor TEB-17231 at the 2023 AACR Annual Meeting
A broadly acting KRAS Inhibitor, TEB-17231, robustly blocks tumor growth and overcomes KRASG12C inhibitor mediated resistance SHANGHAI, March 21, 2023 /PRNewswire/ -- 280Bio, Inc. a clinical stage biotechnology company, focused on the development of precision oncology medicines, today announced ...
Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023
SUZHOU, China, March 21, 2023 /PRNewswire/ -- The 2023 Annual Meeting of American Academy of Dermatology Association (AAD 2023) was held from 17 to21 March 2023 in New Orleans, Louisiana, United States. As one of the largest, most influential and representative of all dermatologic associations, ...
Hovione and Ripple Enter Strategic Partnership to Expand Epidel® Platform into Non-Ophthalmic Space
LISBON, Portugal, March 20, 2023 /PRNewswire/ -- Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel® plat...
Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration
CHENGDU, China, March 17, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) announced its 2022 annual results. Focused on unmet clinical needs, the Company continued to efficiently develop innovative and differentiated pipelines, proactively carry out global strategic collaboration and a...
Hanmi Pharmaceutical's Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in 'The Lancet' & 'European Heart Journal'
SEOUL, South Korea, March 17, 2023 /PRNewswire/ -- Hanmi Pharmaceuticals (128940.KS), a subsidiary of Hanmi Science (008930.KS) in Korea, announced that the results of large-scale clinical trial with Rosuzet have been published in 'The Lancet' and the 'European Heart Journal'. R&D-oriented pha...
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00